2025 Thessaloniki, Greece

I-01 Joăo Abrantes
ADaMO: End-to-end automation of Pharmacometric modelling in drug development, from dataset building to output generation
Wednesday 09:45-11:15
I-02 Nicolas Azzopardi
Mechanistic model of contrast-enhanced ultrasound in colorectal cancer metastasis.
Wednesday 09:45-11:15
I-03 Freya Bachmann
Computing Optimal Drug Dosing with OptiDose: Implementation in NONMEM
Wednesday 09:45-11:15
I-10 Chao Chen
The area under the effect curve as a preclinical-to-clinical translation tool for predicting therapeutic dose of anti-infectives
Wednesday 09:45-11:15
I-11 Henrik Cordes
Species-specific Expression Databases for Physiologically Based Pharmacokinetic Modeling
Wednesday 09:45-11:15
I-20 Mélanie Guhl
Computation of standard errors at finite distance in non linear mixed effects models
Wednesday 09:45-11:15
I-24 Laura Iavarone
Application of the Area Under the Effect Curve as in vivo efficacy driver in Visceral Leishmaniasis
Wednesday 09:45-11:15
I-25 Woojin Jung
Containerized NONMEM and its assistant software in R development environment
Wednesday 09:45-11:15
I-28 Silvia Maria Lavezzi
Translational pharmacology benchmarking of a novel drug candidate for an autoimmune disease
Wednesday 09:45-11:15
I-32 Nicolas Luyckx
Campsis: A generic, easy-to-use and intuitive PK/PD simulation platform based on R packages RxODE and mrgsolve
Wednesday 09:45-11:15
I-35 Frano Mihaljevic
Development of a level A in vitro/in vivo correlation (IVIVC) using applications of the MonolixSuite
Wednesday 09:45-11:15
I-39 Marije Otto
Application of Item Response Theory in Early Phase Clinical Trials: Utilization of a Reference Model to Analyse the Montgomery-Ĺsberg Depression Rating Scale.
Wednesday 09:45-11:15
I-40 Theodoros Papathanasiou
PKPD Exploratory Graphics (xGx) Cheat Sheet
Wednesday 09:45-11:15
I-44 Thao Nguyen Pham
Combining aggregate data and individual patient/subject data in model-based meta-analysis: An illustrative case study of tofacitinib in rheumatoid arthritis patients
Wednesday 09:45-11:15
I-48 Christelle Rodrigues
Using preclinical data to predict human pharmacokinetics of monoclonal antibodies for first-in-human dose setting: A review of five internal case studies
Wednesday 09:45-11:15
I-51 Sergio Sánchez Herrero
Ground-breaking software for modelling, simulation, optimization, estimation and validation applications in drug development timeline processes.
Wednesday 09:45-11:15
I-58 Pauline Traynard
Validation of non-compartmental analysis (NCA) and bioequivalence results of PKanalix with respect to Phoenix WinNonLin and SAS.
Wednesday 09:45-11:15
I-59 carla troisi
Population pharmacokinetics of continuous infusion ampicillin in the treatment of enterococcal infections in adult hospitalised patients
Wednesday 09:45-11:15
I-60 Monika Twarogowska
A library of parent-metabolite models for the MonolixSuite
Wednesday 09:45-11:15
I-62 Marinda van de Kreeke
Identifiability of drug effects in turn-over models with increasing complexity
Wednesday 09:45-11:15